A kind of polypeptide derivative that promotes cell proliferation and its preparation method and application

Abstract

The present invention relates to a polypeptide derivative that promotes cell proliferation, a preparation method and application thereof. The polypeptide derivative has the following structure: Nap-FFGGYGSSSRRAPQT. The present invention also provides a preparation method of the above-mentioned polypeptide derivative. The polypeptide derivative adopts FMOC-solid phase synthesis method. The present invention also provides the use of the above-mentioned polypeptide derivatives in medicines for promoting cell proliferation. The invention is simple to synthesize, and can synthesize active self-assembled polypeptides by solid-phase synthesis, and the raw materials used are amino acids necessary for the human body every day; secondly, because of its self-assembly, it can be slowly released in the body, which significantly solves the problem of IGF- After injection, protein I is easily degraded by various proteases in the body, which leads to the problem of low retention rate in the body; most importantly, it can bind to the IGF-I protein receptor, which in turn can stimulate downstream signaling pathways, promote endothelial cell proliferation, and promote Vascular repair and regeneration.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a polypeptide derivative, in particular to a polypeptide derivative that promotes cell proliferation, and a preparation method and application thereof. Background technique [0002] Insulin-like growth factor I (IGF-I) is a growth factor protein similar to insulin in humans. It plays a vital role in growth and development, metabolism and cell survival, and has a wide range of applications in clinical and life science research. [0003] In clinical practice, there are currently two drugs based on IGF-I protein approved by the US FDA for the treatment of adolescent growth failure (Growth Failiure) and Laron syndrome (Laron syndrome), namely Mecasermin (Mecasermin) ), which is recombinant human IGF-I protein (rhIGF-I); and Mecasermin rinfabate, which is a complex of recombinant human IGF-I protein and recombinant human IGFBP-3 protein (rhIGFBP-3). [0004] In addition to being used as a c...

AI Technical Summary

Problems solved by technology

[0007] First of all: the production cost of existing recombinant proteins is high, the production process is difficult to strictly control, the quality between batches is difficult to guarantee, and industrialization is difficult

[0008] Secondly, the transportation and storage conditions of recombinant proteins are harsh, which further increases their production costs and limits their scope of application

[0009] Again, for the protein itself, it is ineffective to directly inject IGF-I protein into the damaged organ, mainly due to its low retention rate in the tissue (small size: about 7.5KD)

In order to solve these problems, researchers have developed many methods to encapsulate IGF-I and deliver it to designated locations through biocompatible carriers, but none of these studies have achieved clinical application

Images